Investment Thesis
Cogent Biosciences faces severe operational distress with revenue collapsing 65% YoY to just $7.9M while operating losses reached $103.6M. The company is burning approximately $87M in free cash flow per quarter, exhausting its $241.2M cash reserve within 8-9 months, and shows no evidence of a viable path to profitability or revenue stabilization.
Strengths
- Strong balance sheet with $241.2M cash and only $223.2M long-term debt (0.37x D/E ratio)
- Excellent liquidity with 15.14x current ratio providing near-term financial flexibility
- Moderate leverage allows potential for restructuring or asset-based financing
Risks
- Catastrophic 65% YoY revenue decline indicates failed commercialization or major business disruption
- Operating cash burn of $86.9M per quarter with only 8-9 months of cash runway remaining
- Massive operating losses ($103.6M) and negative margins (-1316% operating margin) with no clear inflection point
- Existential risk of cash depletion unless dramatic operational turnaround or external financing materializes
Key Metrics to Watch
- Quarterly revenue trend and product pipeline updates - any stabilization above $7.9M would be critical
- Monthly cash burn rate - deterioration below current levels indicates accelerated distress
- Major partnership or financing announcements - essential for extending runway beyond Q4 2026
Financial Metrics
Revenue
7.9M
Net Income
-97.4M
EPS (Diluted)
$-0.53
Free Cash Flow
-87.3M
Total Assets
903.0M
Cash
241.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,316.3%
Net Margin
-1,236.8%
ROE
-16.0%
ROA
-10.8%
FCF Margin
-1,109.5%
Balance Sheet & Liquidity
Current Ratio
15.14x
Quick Ratio
15.14x
Debt/Equity
0.37x
Debt/Assets
32.7%
Interest Coverage
N/A
Long-term Debt
223.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:26:02.987168 |
Data as of: 2026-03-31 |
Powered by Claude AI